Trousseau's syndrome: cancer-associated thrombosis

被引:155
作者
Ikushima, Soichiro [1 ]
Ono, Ryu [1 ]
Fukuda, Kensuke [1 ]
Sakayori, Masashi [1 ]
Awano, Nobuyasu [1 ]
Kondo, Keisuke [1 ]
机构
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Tokyo, Japan
关键词
Trousseau's syndrome; cancer-associated thrombosis; venous thromboembolism; pulmonary embolism; arterial thrombosis; VENOUS THROMBOEMBOLISM PROPHYLAXIS; MOLECULAR-WEIGHT HEPARIN; AMERICAN SOCIETY; PREVENTION; VALIDATION; COUMARIN; RISK;
D O I
10.1093/jjco/hyv165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Trousseau's syndrome (cancer-associated thrombosis) is the second leading cause of death in cancer patients, after death from cancer itself. The risk of a venous thromboembolism is 4- to 7-fold higher in patients with cancer than in those without cancer. The causes of this impaired coagulation are associated with general patient-related risk factors, and other factors that are specific to the particular cancer or treatment. It is important to assess the risk of thrombotic events in cancer patients and administer effective prophylaxis and treatment. Effective prophylaxis and treatment of venous thromboembolism reduces morbidity and mortality, and improves patients' quality of life. Low molecular weight heparin is the first-line treatment for venous thromboembolism, as an effective and safe means for prophylaxis and treatment, according to guidelines released by international scientific societies. Oral anticoagulation therapy with warfarin is preferable to no therapy. However, warfarin has low efficacy and is associated with high rates of recurrence. If low molecular weight heparin is unavailable, some guidelines recommend the use of vitamin K antagonists that have a target international normalized ratio in the range of 2-3, as acceptable alternatives. Novel oral anticoagulants that directly inhibit factor Xa or thrombin are promising for the prophylaxis of high-risk cancer patients and in the long-term treatment of venous thromboembolism. However, to date, there is insufficient evidence to support the use of these new anticoagulants.
引用
收藏
页码:204 / 208
页数:5
相关论文
共 50 条
[21]   CANCER-ASSOCIATED THROMBOTIC DISEASE Treatment of cancer-associated thrombosis [J].
Lee, Agnes Y. Y. ;
Peterson, Erica A. .
BLOOD, 2013, 122 (14) :2310-2317
[22]   Real world data regarding the management of cancer-associated thrombosis [J].
Tsoukalas, Nikolaos ;
Tsapakidis, Konstantinos ;
Galanopoulos, Michail ;
Karamitrousis, Evangelos ;
Kamposioras, Konstantinos ;
Tolia, Maria .
CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) :289-294
[23]   Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis [J].
Lyman, Gary H. ;
Kuderer, Nicole M. .
THROMBOSIS RESEARCH, 2020, 191 :S79-S84
[24]   Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS) [J].
Font, Carme ;
Nelson, Annmarie ;
Garcia-Fernandez, Tanya ;
Prout, Hayley ;
Gee, Peter ;
Noble, Simon .
SUPPORTIVE CARE IN CANCER, 2018, 26 (09) :3233-3239
[25]   Key points to optimizing management and research on cancer-associated thrombosis [J].
Carmona-Bayonas, A. ;
Sanchez-Canovas, M. ;
Plasencia, J. M. ;
Custodio, A. ;
Martinez de Castro, E. ;
Virizuela, J. A. ;
Ayala de la Pena, F. ;
Jimenez-Fonseca, P. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (02) :119-126
[27]   A Review of the Past, Present and Future of Cancer-associated Thrombosis Management [J].
Ramcharitar, Randy K. ;
Man, Louise ;
Khaja, Minhaj S. ;
Barnett, Merry Ellen ;
Sharma, Aditya .
HEART INTERNATIONAL, 2022, 16 (02) :117-123
[28]   Platelets and Cancer-Associated Thrombosis [J].
Connolly, Gregory C. ;
Phipps, Richard P. ;
Francis, Charles W. .
SEMINARS IN ONCOLOGY, 2014, 41 (03) :302-310
[29]   Mechanisms of cancer-associated thrombosis [J].
Hisada, Yohei ;
Mackman, Nigel .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (03)
[30]   Pancreatic cancer-associated thrombosis [J].
Tam, Tommy H. C. ;
Lui, Rashid N. .
HONG KONG MEDICAL JOURNAL, 2023, 29 (05) :378-379